Back to Clinical Trials Overview

Your search for "Liver Disorders" returned 24 results:


Genomics of Primary Biliary Cirrhosis
Principal Investigator(s): Joseph Odin

Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study toInvestigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection
Principal Investigator(s): Rita Agarwal

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Donald Kotler

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV
Principal Investigator(s): David Ferris

A randomized double-blind controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis B
Principal Investigator(s): Odin, Joseph A

A Phase 2b Dose-Ranging Randomized Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624 a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis
Principal Investigator(s): Charissa Chang

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (CENTAUR)
Principal Investigator(s): Meena Bansal

Simeprevir (SMV)+Sofosbuvir (SOF) with or without Ribavirin (RBV) for Interferon-intolerant or ineligible (IFN-II) Patients with Chronic Hepatitis C (CHC)
Principal Investigator(s): Ritu Agarwal

A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood Disorders with and without HIV Co-Infection
Principal Investigator(s): Ponni Perumalswami

HCC BRIDGE study: Bridge to better outcomes in HCC
Principal Investigator(s): Schwartz, Myron MD

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection
Principal Investigator(s): Rita Agarwal

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
Principal Investigator(s): Meena Bansal

A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3
Principal Investigator(s): Ponni Perumalswami

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor
Principal Investigator(s): Meena Bansal

A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH)
Principal Investigator(s): Charissa Chang

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Joseph Odin

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Principal Investigator(s): Ponni Perumalswami

A Long Term Follow-up Registry Study for Subjects Who Achieve A Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Donald Kotler

A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) andHuman Immunodeficiency Virus (HIV)-1 Coinfection
Principal Investigator(s): Linda Law

An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
Principal Investigator(s): Douglas Dieterich

A Phase 2 Randomized Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the treatment of subjects with chronic hepatitis B and who are currently not on treatment
Principal Investigator(s): Jennifer Leong